Clinical Trial

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-09.
Status change: Not Yet Recruiting → Recruiting 2025-07-30
Trial Details
NCT Number NCT06978920
Lead Sponsor Nuwacell Biotechnologies Co., Ltd.
Conditions Parkinson Disease
Enrollment 48 participants
Start Date 2025-06-06
Primary Completion 2026-07-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-01